KT5720__PKA kinase inhibitor Auristatin F
Product Name
KT5720
Description
PKA kinase inhibitor
Purity
>98% (TLC)
CAS No.
108068-98-0
Molecular Formula
C32H31N3O5
Molecular Weight
537.6
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
Soluble in methanol: clear colorless solution at 5 mg/ml
Source
Synthetic
Appearance
White powder
SMILES
N47C1=C(C6=C(C2=C1N(C3=CC=CC=C23)email protected5OC@@4(C@(C5)(O)C(=O)OCCCCCC)C)C(NC6)=O)C8=C7C=CC=C8
InChI
InChI=1S/C32H31N3O5/c1-3-4-5-10-15-39-30(37)32(38)16-23-34-21-13-8-6-11-18(21)25-26-20(17-33-29(26)36)24-19-12-7-9-14-22(19)35(28(24)27(25)34)31(32,2)40-23/h6-9,11-14,23,38H,3-5,10,15-17H2,1-2H3,(H,3
InChIKey
ZHEHVZXPFVXKEY-UHFFFAOYSA-N
Safety Phrases
Classification:
Specific target organ toxicity-single exposure (Category 1), H370
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H370 Causes damage to organs.
Precautionary statements:
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P307 + P311 IF exposed: Call a POISON CENTER or doctor/ physician.
P321 Specific treatment (see supplemental first aid instructions on this label).
P405 Store locked up.
P501 Dispose of contents/ container to an approved waste disposal plant
Cite This Product
KT5720 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-457)
Alternative Names
(9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo1,2,3-fg:3′,2′,1′-klpyrrolo3,4-i1,6benzodiazocine-10-carboxylic acid hexyl ester
Research Areas
Cancer, Apoptosis, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors
PubChem ID
3844
Scientific Background
KT5720 is a potent and selective inhibitor of protein kinase A (PKA). This compound blocks PKA signaling through competitive inhibition. It causes no significant effect on protein kinase C (PKC), protein kinase G (PKG) or myosin light chain kinase (mlCK). KT5720 has been shown to reversibly arrests human skin fibroblasts in the G1 phase. It is cell permeable.
References
1. Kase H., et al. (1987) Biochem. Biophys. Res. Comm. 142(2): 436–440.
2. Gadbois D.M., Crissman H.A., Tobey R.A., & Bradbury E.M. (1992) Pro. Na. Aca. Sci. USA. 89(18): 8626–8630.
PKA kinase inhibitor
Specific target organ toxicity-single exposure (Category 1), H370
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H370 Causes damage to organs.
Precautionary statements:
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P307 + P311 IF exposed: Call a POISON CENTER or doctor/ physician.
P321 Specific treatment (see supplemental first aid instructions on this label).
P405 Store locked up.
P501 Dispose of contents/ container to an approved waste disposal plant
2. Gadbois D.M., Crissman H.A., Tobey R.A., & Bradbury E.M. (1992) Pro. Na. Aca. Sci. USA. 89(18): 8626–8630.